Pfizer’s Danuglipron Is Done, Sparking M&A Speculation
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.